Lussiana Folleco-Insuasty, Luis Fernando Roa-Wandurraga, Federico Liberman, Diana Ayan, Rodrigo Bagur, Luciano A Sposato
{"title":"Atrial fibrillation detected after stroke: Recent advances and future directions.","authors":"Lussiana Folleco-Insuasty, Luis Fernando Roa-Wandurraga, Federico Liberman, Diana Ayan, Rodrigo Bagur, Luciano A Sposato","doi":"10.1177/17474930261465951","DOIUrl":null,"url":null,"abstract":"<p><p>Prolonged cardiac monitoring has made atrial fibrillation (AF) an increasingly common diagnosis after ischemic stroke. Applied to all patients with ischemic stroke, prolonged cardiac monitoring would result in over a million new AF diagnoses per year worldwide. Almost 10 years after the conceptual inception of AF detected after stroke (AFDAS), several patterns are now consistent across studies. AFDAS is a distinct, mechanistically heterogeneous entity that differs from AF known before stroke in its risk-factor profile, cardiac comorbidity, and its lower rate of ischemic stroke recurrence. Its detection is determined primarily by the monitoring method and increases with earlier and longer-duration monitoring. AF identified on a standard electrocardiogram behaves as a high-burden arrhythmia, resembling AF known before stroke, and should be distinguished from the low-burden AF detected by prolonged monitoring. Important questions remain unresolved. It is unproven that detecting more AF, or detecting it earlier, reduces recurrent ischemic stroke. The low-burden arrhythmia that monitoring increasingly identifies appears to carry a lower embolic risk than the high-burden AF for which anticoagulation was established. Whether patients with low-burden, monitor-detected AFDAS derive net benefit from anticoagulation, the contribution of neurogenic mechanisms, and the thresholds of AF burden that should guide treatment are undefined. Future trials should be powered for recurrent stroke as the primary endpoint.</p>","PeriodicalId":14442,"journal":{"name":"International Journal of Stroke","volume":" ","pages":"895-901"},"PeriodicalIF":6.9000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13392223/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Stroke","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17474930261465951","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Prolonged cardiac monitoring has made atrial fibrillation (AF) an increasingly common diagnosis after ischemic stroke. Applied to all patients with ischemic stroke, prolonged cardiac monitoring would result in over a million new AF diagnoses per year worldwide. Almost 10 years after the conceptual inception of AF detected after stroke (AFDAS), several patterns are now consistent across studies. AFDAS is a distinct, mechanistically heterogeneous entity that differs from AF known before stroke in its risk-factor profile, cardiac comorbidity, and its lower rate of ischemic stroke recurrence. Its detection is determined primarily by the monitoring method and increases with earlier and longer-duration monitoring. AF identified on a standard electrocardiogram behaves as a high-burden arrhythmia, resembling AF known before stroke, and should be distinguished from the low-burden AF detected by prolonged monitoring. Important questions remain unresolved. It is unproven that detecting more AF, or detecting it earlier, reduces recurrent ischemic stroke. The low-burden arrhythmia that monitoring increasingly identifies appears to carry a lower embolic risk than the high-burden AF for which anticoagulation was established. Whether patients with low-burden, monitor-detected AFDAS derive net benefit from anticoagulation, the contribution of neurogenic mechanisms, and the thresholds of AF burden that should guide treatment are undefined. Future trials should be powered for recurrent stroke as the primary endpoint.
期刊介绍:
The International Journal of Stroke is a welcome addition to the international stroke journal landscape in that it concentrates on the clinical aspects of stroke with basic science contributions in areas of clinical interest. Reviews of current topics are broadly based to encompass not only recent advances of global interest but also those which may be more important in certain regions and the journal regularly features items of news interest from all parts of the world. To facilitate the international nature of the journal, our Associate Editors from Europe, Asia, North America and South America coordinate segments of the journal.